FC
REGN icon

FBR & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

FBR & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-17,000
Closed -$3.82M – 54
2013
Q2 		$3.82M Buy
+17,000
New +$3.96M 4.87% 5

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FBR & Co's REGN Position: Q3 2013 in Review

FBR & Co sold out of Regeneron Pharmaceuticals (REGN) in Q3 2013, closing a stake of 17,000 shares — an estimated $3.82M sold.

FBR & Co first reported a position in REGN in Q2 2013 and held it in 1 quarter. The position peaked at $3.82M in Q2 2013. 414 funds tracked by Wall St. Rank hold REGN as of Q3 2013.

  • FBR & Co reported no remaining Regeneron Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • FBR & Co sold 17,000 Regeneron Pharmaceuticals shares in Q3 2013, an estimated $3.82M.
  • FBR & Co first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • FBR & Co's Regeneron Pharmaceuticals position peaked at $3.82M in Q2 2013.
  • 414 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2013.

Based on FBR & Co's 13F filing for Q3 2013, filed 7 Nov 2013.